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Abstract
Dynamic transmission models of influenza are often used in decision-making to identify which vacci-
nation strategies might best reduce influenza-associated health and economic burdens. Our goal was
to use laboratory confirmed influenza cases to fit model parameters in an age-structured, two-type
(influenza A/B) dynamic model of influenza. We compared the fitted model under two different
types of fitting methodologies: using longitudinal weekly case notification data versus using cross-
sectional age-stratified cumulative case notification data. These two approaches allow us to compare
model predictions when using two different types of model fitting procedures, according to data
availability. We find that the longitudinal fitting method provides best fitting parameter sets that
have a higher variance between the respective parameters in each set than the cross-sectional cu-
mulative case method. Also, model predictions–particularly for influenza A–are very different for
the two fitting approaches under hypothetical vaccination scenarios that expand coverage in either
younger age classes or older age classes. The cross-sectional method predicts much larger decreases
in total cases from baseline vaccination coverage than the longitudinal method. Also, the longitudi-
nal method predicts that vaccinating younger age groups yields greater declines in total cases than
vaccinating older age groups, whereas the cross-sectional method predicts the opposite. These re-
sults show that the type of data used to fit a dynamic transmission model can produce very different
outcomes, hence multiple fitting methods should be used whenever possible.
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1. Introduction1
Seasonal influenza imposes a significant health burden each year, reducing the quality of life2
for many across the globe [1]. Although often viewed as a mild illness typically causing school3
or workplace absenteeism, influenza can cause significant complications for vulnerable populations4
such as the elderly or those with weakened immune systems. In order to combat influenza, health5
jurisdictions may implement vaccination programmes (such as the Universal Influenza Immunization6
Program in Ontario, Canada) that may target certain age groups, professions, or make vaccines7
widely available to the public.8
Dynamic transmission models can be used to evaluate the effectiveness of control strategies9
for seasonal influenza, such as targeted vaccinations and vaccine types [2, 3, 4, 5, 6, 7, 8, 9, 10,10
11]. These models are increasingly essential for decision-making regarding vaccine implementation,11
since in silico experiments regarding optimal age of vaccination can be done when experiments in12
real populations are impossible or impractical. For example, a frequent problem addressed in the13
literature is finding an optimal approach to distributing vaccines [12]. Some research has found that14
targeting younger age groups produces the most benefit in limiting influenza spread and improving15
health outcomes across a population [13, 14, 15, 16, 17, 18]. However, other research has also shown16
this may not be the case in all circumstances [19, 2]. In the past, influenza transmission models17
have either chosen parameters without a fitting process [20, 21], have been fitted to a single year18
using cross-sectional cumulative cases for that season [22, 23], to weekly time series longitudinal19
data [24, 8], to influenza like illness (ILI) data, assuming ILI incidence follows the same patterns as20
seasonal influenza [22, 24], or incorporating data of laboratory confirmed influenza cases [8, 23].21
Here, we create an age stratified dynamic transmission model of seasonal influenza following22
similar approaches to Thommes et al. [9], and use positive influenza specimen tests for parameter23
estimation. Our research questions are (1) to determine whether a dynamic two-strain (influenza24
A/influenza B) transmission model can be fitted to longitudinal time series data of weekly laboratory25
confirmed influenza cases spanning multiple years, and (2) to compare the resulting fit and model26
predictions of the impact of vaccination to the case where the model is fitted only to non-longitudinal,27
cross-sectional data on age-stratified cumulative attack rates instead. This comparison will help28
determine how the quality and type of data can impact a model’s outcomes, as some regions have29
more complete surveillance than others. In our model, we seek to estimate the key parameters of30
influenza transmission for both A and B strains. Previous models have not solely used laboratory31
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confirmed case data for both A and B strains of seasonal influenza, or used the same fitting process to32
directly compare results when fitting to longitudinal time series data and cross-sectional cumulative33
case data over multi-year time spans.34
2. Methods35
Our model is a compartmental age structured model [25], and we will fit important transmission36
parameters to longitudinal influenza case data, as well as cross-sectional age stratified case data.37
Incorporating age structure is a critical factor, as population contact patterns, and therefore influenza38
transmission, depend on age. Details of the model development are given in the following sections.39
2.1. Population Demographics40
Our model uses age compartments 1 year in size, starting from 0-1 years, and ending at 99+ years41
[24, 9]. The population size and age structure are modelled after the province of Ontario, Canada,42
to remain consistent with our data on influenza incidence. We also chose Ontario as our study43
population on account of its relatively large population size and presence of a universal influenza44
immunization program in the province. When we age the population, we use yearly population45
projections given by Ontario’s Ministry of Finance, which are based on census data, birth/death46
rates, immigration, and emigration [26, 27, 28], or census data (for the model’s 2011 population)47
[29]. Due to the model’s high age resolution, we are able to specify age dependent contact rates.48
These contact rates play a crucial role in influenza transmission, and we use a contact matrix which49
specifies the mean daily duration of contact time in minutes between age groups [30]. These contact50
data are based on studies conducted in the United States, and thus we are making the assumption51
that contact rates in the region we are modelling are similar.52
2.2. Influenza Incidence Data and Epidemiology53
All data used in our study are publicly available. Data on confirmed influenza cases are available54
for the province of Ontario, Canada from the years 2010 to 2015 [31]. The data give the weekly55
number of confirmed cases in the province for the specified years. For fitting our model to age56
stratified cumulative cases, we use the years 2011 to 2016 due to these years having the required57
data available. The age categories used in the fitting are 0-19, 19-65, and 65+. In our model, we58
will consider influenza cases caused by both the A and B strains.59
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The influenza virus in our model has a susceptible-infected-recovered-vaccinated natural history.60
For transmission, we use the contact hypothesis [30] where our contact matrix C taken from Table61
1 in Zagheni et al [30] defines the average daily time of contact between age groups. We define βi62
to be the probability that an individual in age group i becomes infected after being in contact with63
an infectious individual, which in our case is constant across age groups. The time varying force of64










where Ij is the number of infected individuals in age group j and Nj is the size of age group j.67
Additionally, influenza incidence shows a prominent annual recurrence in the winter months, which68
has been thought to be caused by a variety of factors such as temperature, humidity, and changes69
in contact patterns [32, 33, 34]. To ensure this seasonal variation in our model, we use a sinusoidal70







where A is the amplitude of the seasonality function which determines the variation of the basic73
reproductive numberR0, and δ determines on what day the maximum value of the seasonality occurs74
(δ = 0 corresponds to January 1). This formulation is similar to previous work modelling the same75
dynamic [24, 9, 20], and we use the derivation found in Thommes et al. [9] to relate βi to R0.76
Finally, infected individuals recover at a constant rate γ. Also, to model the antigenic drift of77
the influenza virus [36], we force individuals that have been infected to lose their immunity at a78
constant rate. In our model, natural immunity loss occurs at rate ρN .79
2.3. Vaccination80
In Ontario, the primary types of vaccines used are the trivalent inactivated vaccine, the quadri-81
valent inactivated vaccine, and the quadrivalent live-attenuated vaccine [37]. In this region, the82
recommended individuals to receive vaccination are those aged 6 months and older, and especially83
individuals in high risk groups or those who may directly transmit to high risk groups [37].84
In our model, we specify a proportion of individuals in each age group to become vaccinated85
each year. At the time of vaccination, a vaccinated individual in age group i receives vaccine86
induced immunity according to the vaccine’s efficacy with probability εi, and remains susceptible87
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with probability 1 − εi. Vaccine efficacy is set to 65% for ages < 65 and 55% for older age groups88
[38, 39, 40]. We also assume there is no partial immunity conferred with an inefficacious vaccination89
[24, 9]. For vaccination coverage rates, we use data from the studies by [41, 42, 43, 44], and based on90
the age ranges given, we use linear interpolation to restore our yearly age resolution. The baseline91
coverages are 0-1 years: 3.7%, 1-2 years: 7.4%, 2-11 years: 29.48%, 12-19 years: 36%, 20-49 years:92
25.5%, 50-64 years: 48%, 65-74 years: 73%, 75-84 years: 84%, and 85+ years: 82% [41, 42, 44, 43].93
Much like natural immunity, vaccine acquired immunity wanes at a constant rate of ρV . In our94
model, we choose ρV to be a fitted parameter rather than choosing it as a fixed value or assuming95
it to be equal to ρN , as was used in previous studies [24, 9, 20]. Finally, those who become infected96
regardless of vaccinating will not show a reduction in infectiousness.97
2.4. Model Structure98
Our system of differential equations consists of susceptible Si(t), infected Ii(t), recovered Ri(t),99
and vaccinated Vi(t) individuals where i denotes the respective age class an individual belongs to.100
dSi
dt
= −λi(t) + ρNRi + ρV Vi (3)101
dIi
dt
= λi(t)− γIi (4)102
dRi
dt
= γIi − ρNRi (5)103
dVi
dt
= −ρV Vi (6)104
105
The system is integrated with a time step of one day allowing for precise calculation the the daily106
force of infection as well as sufficient numerical solution accuracy. We use the MATLAB package107
ODE4 to fulfill our fixed time step requirement. In addition to the 5 year time period for which we108
have historical influenza incidence data, we run our model with a 10 year burn in period. During109
the burn in period, we use the 2010 population demographics and maintain the same vaccine uptake110
rates that were used during our period of interest.111
Each year we choose a day near the end of summer (August 31), to age the population [20, 24, 9].112
Individuals are moved to the next age class in one time step, and those in the 99+ age category113
remain. Then, the population is scaled to match the demographics of the next year’s population,114
as projected by Statistics Canada and Ontario Ministry of Finance. If these more in depth metrics115
are not available, population birth and death rates may simply be used. Newborns entering the first116
age category all populate the S0 compartment.117
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Next, vaccination occurs on October 1 of each year because in our selected region the majority118
of vaccination occurs in the fall. In our model, we make the approximation that vaccination of the119
population occurs before each influenza epidemic begins. Then, at a point tseed we add an external120
value λext to the force of infection for the remainder of the influenza season. This is a hybrid between121
models by Goeyvaerts et al. [24] and Thommes et al. [9] as we find this small addition to the force122
of infection grants a smoother transition into each new influenza season as opposed to infecting a123
bulk amount of individuals all at once on tseed. In addition, for the period of time between seasons,124
we remove λext so no additional new cases arise. A diagram showing the primary transitions of125
our model is shown in Figure 1. Vertical arrows represent aging, and on the day of the year the126
population is aged, members in each compartment are added to the corresponding compartment in127
the next age group.128
Figure 1: Diagram of the age-stratified SIRS compartmental model with vaccination. See Methods for definitions of
parameters and variables.
2.5. Parameter Fitting129
We compared two methods of fitting our model’s parameters: fitting the parameters to longi-130
tudinal weekly case notification data spanning multiple years (we will call this the ”longitudinal131
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method”) and fitting the parameters to cross-sectional age-stratified data that lack a temporal vari-132
able (we call this the ”cross-sectional method”).133
2.5.1. Longitudinal Method134
We aim to fit the parameters of our model to multi-year longitudinal time series data taken from135
[31] in a similar manner to Goeyvaerts et al. [24]. However, we use laboratory confirmed influenza136
specimen cases instead of ILI incidence data used by previous models which are based on reported137
influenza-like symptoms rather than laboratory confirmed cases.138
In order to quantify the goodness of fit for a given parameter set, we use a least squares approach:139
historical weekly incidence of the number of positive influenza cases is compared to our model’s140
corresponding output. We define the number of historical reported cases in week w to be IHw , and141
the number of cases given by the model in week w to be IMw . In order to directly compare the142
two quantities, we use the parameter α introduced by Goeyvaerts et al. [24] to scale the model143
incidence. Here, α captures the probability that an infected individual is symptomatic, visits a144
medical practitioner and gets tested for the influenza virus which returns a positive result. The sum145
of squares error is then146 ∑
∀w
(
IHw − (αIMw )
)2
. (7)147
To evenly sample the parameter space, we use Latin hypercube sampling [45] to generate 35,000148
parameter combinations. Parameter descriptions and fitting ranges (that is, Latin hypercube sam-149
pling ranges) are given in Table 1. We then determine each parameter set’s sum of squares score150
over a simulation run. Next, we utilize MATLAB’s GlobalSearch algorithm to search for optimal151
parameter combinations using the parameter sets that offered the lowest sum of squares values.152
GlobalSearch attempts to find a function’s global minimum, and initializes its search over the pa-153
rameter space from a user defined start point. In our case, the function we are seeking to minimize154
is the sum of squares score of our system of differential equations. The input points are used by the155
solver to determine an initial estimate for a basin of attraction, and the algorithm also generates a156
set of trial points to be used in finding the minimum. Additionally, upper and lower bounds may157
be specified for each parameter, which we define as the same bounds used in the Latin hypercube158
sampling. Any number of runs of the GlobalSearch algorithm may be performed, using a different159
starting point corresponding to the parameter sets obtained from the Latin hypercube samples for160
each run. Moreover, maximum runtimes may be specified as well.161
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Table 1: Parameter descriptions, fitting ranges and literature sources.
Parameter Description Fitting Range Source
A Amplitude of seasonality function 0 - 1.0 Maximum range.
tseed
Days after vaccination when infected are




δ Timing of seasonality function peak (days)
-10-45
-60-10**
Assumption*; forces R0 peak to fall between November and January
R0 Average basic reproduction number 1.0-2.5
[46], peak range also encompasses estimates of pandemic
influenza strains [47, 48].
γ Mean latent plus infectious period 4 days (fixed) [49]




ρV Vaccine conferred waning immunity rate 0.5-1.5 years
Encompasses the range used by similar models [9, 24], and based on research
deducing that antibodies may wane near the end of a season [50].
λext
Infections originating from an outside source.
(Value added to the force of infection)
0.01-0.2 Assumption.
α Scaling factor of model incidence 0.0005-0.15 Estimate based on [51].
*Also based on preliminary Latin hypercube sampling. Wider ranges were originally used, but the best results were contained within
ranges shown above.
**Ranges used for influenza B.
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Due to the stochastic nature of the process, more runs may result in lower least squares fits, and162
the available computational resources will be a determinant of how many initial points, and therefore163
runs, of GlobalSearch are used. In our analysis, we use the 50 best performing parameter sets164
obtained from the Latin hypercube sampling to use as initial points for the GlobalSearch algorithm.165
We also tested a group of random initial points gathered from the top 15% of parameter sets from166
the Latin hypercube sampling, but they did not provide better results (lower sum of squares) than167
the aforementioned top 50 sets.168
2.5.2. Cross-Sectional Method169
For fitting age-stratified cumulative cases over the 5-year period, the available data is from170
Canada as a whole [31] (Ontario level data does not include age-stratified cases). Thus, we scaled171
the cases by the proportion of the Canadian population that lives in Ontario in order to remain172
consistent with the longitudinal method’s fitting.173
The fitting for the cross-sectional method was identical to the longitudinal method, except we174
did not compute a difference of squares from the model output to the historical data for each week.175
Instead, the difference of squares was computed over total cases over the entire 5-year period. Also,176
the model output of each age category (ages 0-19, 19-65, and 65+) was separately compared to177
the corresponding historical data, such that we attempted to fit age-specific number of cases in the178
model to the age-specific profile observed in the data.179
3. Results180
3.1. Parameter Fitting Comparison181
Time series of the best parameter combinations resulting from the the fitting processes for in-182
fluenza A and B for the longitudinal method are shown in Figure 2 and Table 2. The plotted results183
are compared to the historical laboratory confirmed cases over the time period. We used a separate184
fitting process for each strain, although we assume that the vaccine efficacy and the infectious peri-185
ods are the same for both. The largest differences in our model emanate from the 2012 season for186
influenza B. Most parameter sets undershoot the peak in this season, although some achieve much187
closer fits.188
Simulations using the cross-sectional method produce the parameter combinations shown in189
Table 3, with the results for each age category shown in Figure 3 A,B. Age-stratified results from190
9






















Figure 2: Time series of confirmed influenza cases (black) and the fitted model (grey) for (A) Influenza A and (B)
Influenza B. Shaded region represents 95% confidence intervals.
Table 2: Best fitting parameter values (mean and standard deviation) for the longitudinal method.
Parameter Mean Value, A Strain Std. Dev. Mean Value, B Strain Std. Dev.
A 0.6304 0.2211 0.3115 0.1269
tseed (day) 35.43 23.89 71.50 32.06
δ (day) 21.15 10.85 -25.14 19.26
R0 1.424 0.3195 1.322 0.3302
ρN (days) 593 237 1408 133
ρV (days) 468 88 427 169
λext 0.0965 0.0731 0.1108 0.0731
α 0.002608 0.0008535 0.004065 0.006953
the longitudinal model are included for comparison in panels C and D. In the cross-sectional method191
results, the variance of total cases produced by the parameter sets for influenza A (Figure 3A) in192
each age category are much lower than that of influenza B (Figure 3B). This could stem from the193
fitting process, and how Globalsearch attempts to find optimal parameter combinations to match the194
age-stratified data. In the case of influenza A, each search has parameters converge to very similar195
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values, whereas the final values for influenza B have much higher variance in comparison. This could196
be due to how the infections are spread out across each age category. For example, influenza A has197
many more cases in the ages 19+ than the ages 0-18. However, influenza B’s cases are evenly spread198
across all ages.199
Table 3: Best fitting parameter values (mean and standard deviation) for the cross-sectional method.
Parameter Mean Value, A Strain Std. Dev. Mean Value, B Strain Std. Dev.
A 0.4405 0.06101 0.4904 0.1131
tseed (day) 46.16 26.14 59.84 36.14
δ (day) 12.02 14.64 -25.70 20.69
R0 1.003 0.01747 1.044 0.09240
ρN (days) 416 68 464 238
ρV (days) 548 11 550 0
λext 0.06387 0.03514 0.1411 0.06227
α 0.0935 0.02440 0.004088 0.0008010
For influenza A, the primary differences in parameters for the two fitting methods stem from the200
parameters A (seasonality amplitude), R0 (average basic reproduction number), and α (incidence201
scaling factor). For the seasonality amplitude, we notice that when not required to meet multiple202
varying seasonal peaks as we did in the longitudinal method, the average amplitude is lower with203
less variance in the cross-sectional method fits than in its longitudinal counterparts. Similarly,204
the average R0 value amongst the parameter sets follows the same pattern: in the cross-sectional205
method’s fits, the average value and variance amongst the sets is lower than the values seen in the206
longitudinal method’s fits. Finally, α is much larger in the cross-sectional method’s fits.207
For influenza B, the biggest differences in parameters for the two fitting methods stem from R0208
and the waning immunity rates ρN and ρV . Similarly to influenza A, the average basic reproduction209
number is smaller and has less variance amongst the sets in the cross-sectional method compared to210
the longitudinal method’s parameters. Also, the average natural waning immunity rate is smaller as211
well. An interesting note is that the vaccine conferred waning immunity rate takes on its maximum212
allowed value in all of the sets for the cross-sectional method. A similar, but less extreme, shift213
11

















































Figure 3: Age-stratified cumulative cases for influenza A and B compared to empirical targets in our model. Target
number of cases from the emprical data are given by X’s where applicable. (A) Cross-sectional method for influenza
A. (B) Cross-sectional method for influenza B. (C) Longitudinal method with age-stratified results for influenza A.
(D) Longitudinal method with age-stratified results for influenza B. From bottom to top, each line in each boxplot
shows the following information: minimum value, first quartile, median, third quartile, maximum value. Red crosses
are considered outliers.
towards the maximum ρV value occurs in the influenza A parameter sets as well.214
3.2. Projected Impact of Expanded Vaccination Coverage215
These results may be further tested by observing the impact of implementing different vaccination216
scenarios or strategies for vaccine allocation approaches. Here, we test the changes in outcomes of217
our model with a targeted vaccine allocation in a scenario where a health jurisdiction is expanding218
their influenza vaccination program.219
When expanding vaccination coverage, an important consideration is targeted distribution of220
vaccines. The two main strategies are to target children, who are believed to be responsible for the221
majority of transmission, or to target high risk individuals and age groups, such as the elderly. To222
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test these two scenarios, we will increase the vaccine uptake of younger aged age groups in our model223
(ages 0-18) by 30% for each age, a strategy which has been believed to indirectly protect other age224
groups as well [18, 17, 16]. Then, we compare these results to increasing the total number of vaccines225
administered by the same amount in older age groups instead, which in our population is the ages226
55+.227
With the longitudinal fitting method for influenza A, vaccinating younger age groups produces228
a 24.53% drop in total cases on average from baseline vaccination (Figure 4A and Figure 5C).229
When targeting older age groups, we see an average reduction in total cases of 13.86%. Total mean230
confirmed cases and their 95% CIs are found in Table 4. Thus, the vaccination program aimed at231
the younger age classes provides a small benefit in total case reduction on average compared to a232
similar program targeting older ages. This stems from the low baseline vaccine uptake in children233
and their high contact rates with each other as well as middle aged adults. In the case of influenza234
B, targeting the younger ages gives an average 19.52% drop in total cases, whereas targeting the235
older age groups gives an average 24.27% drop in the mean (Figure 4B and Figure 5D). Total mean236
confirmed cases and their 95% CIs are found in Table 4. In this case, vaccinating older age groups237
produces a small but largely negligible average reduction in the mean of total cases across parameter238
sets used.
Table 4: Mean number of cases for influenza strains A and B under different vaccination scenarios.
Strain Baseline (95% CI) Vac. Prog. 0-18 (95% CI) Vac. Prog. 55+ (95% CI)
Longitudinal Method
Influenza A 28,787 (± 2,652) 21,725 (±2, 392) 24,797 (±3, 134)
Influenza B 7,483 (±914) 6,022 (±935) 5,667 (±1, 072)
Cross-Sectional Method
Influenza A 35,833 (±390) 24,173 (±597) 10,947 (±607)
Influenza B 12,861 (±785) 8,760 (±505) 6,410 (±646)
239
Using the cross-sectional method, influenza A results differ from the longitudinal method. In this240
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Figure 4: Time series of confirmed influenza A and B cases in the model under different vaccination scenarios for (A)
Influenza A and (B) Influenza B.
case, vaccinating older age groups results in the best case reduction (Figure 5A with comparison241
to the longitudinal model in Figure 5C). When increasing vaccination rates in the ages 55+, we242
see less than half the total cases than when expanding vaccination amongst ages 0-18. Total mean243
confirmed cases from the simulations are found in Table 4. For influenza B, vaccinating the younger244
age groups yields a 31.89% reduction in mean cases compared to baseline, and vaccinating older245
age groups provides a 50.16% reduction (Figure 5B with comparison to the longitudinal model in246
Figure 5D). Total mean confirmed cases from the simulations are found in Table 4. In general, the247
cross-sectional method’s fitting predicts a much larger decrease in total cases for any vaccination248
expansion strategy than the longitudinal time series fitting method. These results reveal that the249
varying types of data that can be used to fit a predictive model of influenza transmission can produce250
very different results.251
4. Discussion252
We have designed and implemented an age-stratified dynamic transmission model of seasonal253
influenza for both A and B influenza types. The model parameters were fit to laboratory confirmed254
influenza cases from the years 2010-2015 in the province of Ontario, Canada, as well as age-stratified255
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Figure 5: Cross-sectional method results of model predictions for influenza A and B cases under different vaccina-
tion scenarios, including comparison to the longitudinal method’s corresponding results. Subpanels show number of
cases for (A) Influenza A, (B) Influenza B, (C) Longitudinal method with age-stratified results for influenza A, (D)
Longitudinal method with age-stratified results for influenza B. From bottom to top, each line in each boxplot shows
the following information: minimum value, first quartile, median, third quartile, maximum value. Red crosses are
considered outliers.
cumulative case data from the years 2011-2016 in Canada. We also used this model to evaluate256
vaccine expansion strategies which target certain age groups.257
Using the cross-sectional method, the variance amongst the respective parameters in each of the258
50 best sets is generally smaller than that of the variance amongst the parameters found using the259
longitudinal method. Also, when introducing vaccination scenarios targeting different age groups,260
outcomes from using parameters derived from the two types of data differ- particularly for influenza261
A. For example, the cross-sectional method’s data predicts much larger decreases in total cases from262
baseline vaccination coverage than the time series data. Additionally, those simulations show that263
vaccinating older age groups will provide the most benefit in reducing the total number of cases in264
the population. Using the longitudinal method, results show that vaccinating younger age groups265
provides a moderate total case reduction for influenza A, and vaccinating older age groups provides266
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a slight total case reduction for influenza B.267
Our model makes some simplifying assumptions. For example, the parameter α, which represents268
the rate at which an infected individual is symptomatic and visits a physician who in turn administers269
a laboratory test for influenza which returns positive, is constant across all age groups. In reality,270
this may not be the case as some age groups may be more likely to visit a physician after becoming271
ill, or physicians may be more likely to administer tests for certain age groups. We also assume272
that the laboratory confirmed case data is a consistently uniform sample of all influenza cases.273
However, physicians may send in more tests depending on the time of year or when they perceive274
the prevalence of influenza is higher. Finally, we assume that vaccine efficacies are the same for both275
A and B strains, and that the infectious period is the same for both as well [9].276
There are some differences in the data used which hinder direct comparisons. The age-stratified277
cumulative case data gives country wide cases, whereas the time series data is for the province of278
Ontario. Although we scale the number of cases country wide by the proportion of Canada that lives279
in Ontario, the cases will still not be directly comparable. Moreover, the age-stratified cumulative280
case data available covers a one year difference from the time series data, causing some discrepancy281
in the number of cases over each 5 year span.282
Different regions will often have varying types of data available for influenza attack rates. In this283
work, we have considered weekly time series confirmed influenza cases and age-stratified cumulative284
cases, but other research has utilized ILI incidence as well [24, 8, 52]. We have shown that when285
using an identical fitting process, these different types of data used to fit the model can produce286
varying results. Thus, when fitting a dynamic transmission model for influenza, the quality of case287
notification data used is an important aspect that impacts model outputs.288
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